Dependence receptors: new targets for cancer therapy.
apoptosis
cancer hallmarks
treatment resistance
tumor progression
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380
Informations de publication
Date de publication:
08 11 2021
08 11 2021
Historique:
revised:
11
08
2021
received:
30
04
2021
accepted:
11
08
2021
pubmed:
21
9
2021
medline:
23
11
2021
entrez:
20
9
2021
Statut:
ppublish
Résumé
Dependence receptors are known to promote survival and positive signaling such as proliferation, migration, and differentiation when activated, but to actively trigger apoptosis when unbound to their ligand. Their abnormal regulation was shown to be an important feature of tumorigenesis, allowing cancer cells to escape apoptosis triggered by these receptors while promoting in parallel major aspects of tumorigenesis such as proliferation, angiogenesis, invasiveness, and chemoresistance. This involvement in multiple cancer hallmarks has raised interest in dependence receptors as targets for cancer therapy. Although additional studies remain necessary to fully understand the complexity of signaling pathways activated by these receptors and to target them efficiently, it is now clear that dependence receptors represent very exciting targets for future cancer treatment. This manuscript reviews current knowledge on the contribution of dependence receptors to cancer and highlights the potential for therapies that activate pro-apoptotic functions of these proteins.
Identifiants
pubmed: 34542930
doi: 10.15252/emmm.202114495
pmc: PMC8573599
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14495Informations de copyright
© 2021 The Authors Published under the terms of the CC BY 4.0 license.
Références
Cancer Cell. 2013 Nov 11;24(5):673-85
pubmed: 24139859
EMBO J. 2001 Jun 1;20(11):2715-22
pubmed: 11387206
PLoS One. 2014 Mar 19;9(3):e92311
pubmed: 24647424
Drug Des Devel Ther. 2016 Aug 01;10:2443-59
pubmed: 27536065
J Natl Cancer Inst. 2011 Apr 20;103(8):645-61
pubmed: 21464397
Int J Cancer. 2012 Jun 15;130(12):2912-21
pubmed: 21796631
Ther Adv Med Oncol. 2020 Jun 02;12:1758835920926796
pubmed: 32536979
J Cell Biol. 2001 Oct 29;155(3):459-70
pubmed: 11684710
Mol Cell Biol. 2006 Aug;26(16):6209-22
pubmed: 16880530
Gastroenterology. 2007 Dec;133(6):1840-8
pubmed: 17967459
Neuron. 1994 Jul;13(1):187-201
pubmed: 8043276
Cancer Res. 2018 Feb 15;78(4):938-949
pubmed: 29259010
Clin Cancer Res. 2017 May 15;23(10):2565-2574
pubmed: 27815356
Cancers (Basel). 2018 Jan 04;10(1):
pubmed: 29300322
EMBO J. 2000 Aug 1;19(15):4056-63
pubmed: 10921886
Gynecol Oncol. 2003 Feb;88(2):123-9
pubmed: 12586590
Oncotarget. 2017 Feb 7;8(6):10264-10273
pubmed: 28052014
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4850-5
pubmed: 18353983
Cell Death Differ. 2009 Oct;16(10):1344-51
pubmed: 19543238
Trends Pharmacol Sci. 2001 Jun;22(6):306-15
pubmed: 11395159
J Invest Dermatol. 2013 May;133(5):1311-20
pubmed: 23223138
Cancer Res. 2019 Jul 15;79(14):3651-3661
pubmed: 31088838
Elife. 2016 Jun 10;5:
pubmed: 27282385
Cell Death Discov. 2019 May 1;5:91
pubmed: 31069116
Cancer J. 2013 Jul-Aug;19(4):316-23
pubmed: 23867513
Oncoimmunology. 2020 Mar 3;9(1):1729299
pubmed: 32313717
Cell Death Dis. 2015 Oct 15;6:e1922
pubmed: 26469970
FEBS J. 2018 Nov;285(21):3909-3924
pubmed: 29776009
Cell Death Differ. 2007 Apr;14(4):752-64
pubmed: 17186028
EMBO Mol Med. 2021 Nov 8;13(11):e14495
pubmed: 34542930
Biomarkers. 2012 Nov;17(7):663-7
pubmed: 22889408
Mol Cancer. 2017 Feb 16;16(1):41
pubmed: 28209166
Cell Stem Cell. 2019 Jan 3;24(1):41-53
pubmed: 30609398
Gastroenterology. 2011 Dec;141(6):2218-2227.e5
pubmed: 21864475
Exp Cell Res. 2018 Oct 1;371(1):63-71
pubmed: 30056064
Oncogene. 2007 Dec 6;26(55):7684-91
pubmed: 17546043
Sci Adv. 2021 Apr 16;7(16):
pubmed: 33863723
Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
pubmed: 12516034
Am J Pathol. 2010 Sep;177(3):1087-94
pubmed: 20671266
Mol Cell. 2018 Nov 1;72(3):413-425.e5
pubmed: 30293784
Hepatology. 2014 May;59(5):2010-21
pubmed: 24122846
Anticancer Res. 2001 Nov-Dec;21(6B):4265-70
pubmed: 11908680
Brain Commun. 2020 Oct 18;2(2):fcaa175
pubmed: 33305261
Cancer Lett. 2020 Mar 1;472:81-96
pubmed: 31838083
Nature. 2010 Sep 2;467(7311):59-63
pubmed: 20811452
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3416-21
pubmed: 11248093
BMC Cancer. 2016 Nov 15;16(1):892
pubmed: 27846823
Curr Opin Chem Biol. 2017 Jun;38:62-69
pubmed: 28371692
Biochim Biophys Acta. 2009 Feb;1793(2):231-8
pubmed: 18948148
FASEB J. 2012 Apr;26(4):1549-58
pubmed: 22198383
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Science. 2003 Aug 8;301(5634):843-6
pubmed: 12907805
Proc Natl Acad Sci U S A. 2008 May 13;105(19):6870-5
pubmed: 18463290
F1000 Biol Rep. 2010 Jun 23;2:
pubmed: 20948786
Tumour Biol. 2016 Sep;37(9):11903-11907
pubmed: 27067437
Biochem J. 2017 Sep 20;474(19):3269-3306
pubmed: 28931648
Nat Cell Biol. 2004 Aug;6(8):749-55
pubmed: 15258591
Front Oncol. 2018 Jul 02;8:248
pubmed: 30013950
Front Oncol. 2019 Jul 09;9:571
pubmed: 31355133
Oncogene. 2013 Aug 29;32(35):4064-77
pubmed: 23001042
Crit Rev Oncol Hematol. 2020 Aug;152:103011
pubmed: 32521311
BMB Rep. 2019 Apr;52(4):239-249
pubmed: 30670153
PLoS Genet. 2013;9(7):e1003552
pubmed: 23874207
J Biol Chem. 2003 May 9;278(19):17483-90
pubmed: 12598531
Curr Pharm Des. 2014;20(17):2849-80
pubmed: 23944364
Med Oncol. 2014 Jul;31(7):966
pubmed: 24878698
Oncol Lett. 2020 Dec;20(6):379
pubmed: 33154777
Cancer Lett. 2021 Sep 28;516:28-35
pubmed: 34077783
Oncogene. 2013 Jan 31;32(5):631-40
pubmed: 22410777
PLoS Biol. 2013;11(8):e1001623
pubmed: 23940460
Sci Signal. 2010 Dec 07;3(151):ra87
pubmed: 21139139
Science. 1993 Jul 16;261(5119):345-8
pubmed: 8332899
Tumour Biol. 2017 Apr;39(4):1010428317698388
pubmed: 28443497
PLoS One. 2013 May 28;8(5):e63765
pubmed: 23723997
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4173-8
pubmed: 12655055
PLoS One. 2011;6(10):e26918
pubmed: 22046410
EMBO Mol Med. 2016 Aug 01;8(8):863-77
pubmed: 27378792
Prostate. 2011 May;71(6):649-58
pubmed: 20949546
Neuron. 1994 Jul;13(1):203-15
pubmed: 7519025
J Clin Pathol. 2007 Nov;60(11):1226-31
pubmed: 17965221
J Clin Invest. 2013 Jul;123(7):2935-47
pubmed: 23778138
Mol Cancer. 2010 Jun 22;9:157
pubmed: 20569463
Curr Opin Oncol. 2010 Jan;22(1):46-54
pubmed: 19934758
Mol Ther. 2011 Dec;19(12):2201-12
pubmed: 21829174
Ann Surg Oncol. 2002 Aug;9(7):610-6
pubmed: 12167573
Cell Death Differ. 2005 Aug;12(8):1021-30
pubmed: 15933741
BMC Cancer. 2009 Jan 10;9:9
pubmed: 19134212
Cell Death Differ. 2005 Aug;12(8):1031-43
pubmed: 16015380
Mol Cancer Ther. 2017 Apr;16(4):671-680
pubmed: 28138031
Development. 2015 Jan 15;142(2):258-67
pubmed: 25564622
Cell Death Differ. 2016 Feb;23(2):323-32
pubmed: 26206087
BMC Cancer. 2016 Oct 6;16(1):772
pubmed: 27716118
Blood. 2008 Aug 15;112(4):1269-79
pubmed: 18524989
Mol Cell. 2013 Sep 12;51(5):632-46
pubmed: 24034695
Urol Oncol. 2020 Jul;38(7):640.e1-640.e12
pubmed: 32156466
Oncotarget. 2016 Dec 27;7(52):87431-87448
pubmed: 27911862
J Biol Chem. 2003 Oct 24;278(43):42161-9
pubmed: 12913006
EMBO J. 2005 Mar 23;24(6):1192-201
pubmed: 15729359
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9951-6
pubmed: 21628563
Cancer Res. 2006 Jun 15;66(12):6312-8
pubmed: 16778208
Cancer Gene Ther. 2018 Feb;25(1-2):18-26
pubmed: 29234153
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Elife. 2020 Feb 24;9:
pubmed: 32091387
Mol Cell Biol. 2004 Dec;24(23):10328-39
pubmed: 15542841
Oncogene. 2020 Jan;39(1):151-163
pubmed: 31462708
Genes Dis. 2016 Mar;3(1):3-6
pubmed: 28491932
Neoplasia. 2009 Dec;11(12):1292-300
pubmed: 20019837
Nat Commun. 2016 Apr 19;7:11184
pubmed: 27091502
Int J Cancer. 2011 Nov 15;129(10):2337-48
pubmed: 21225626
Eur J Pharmacol. 2017 Sep 15;811:180-190
pubmed: 28554854
Cancer Med. 2019 Sep;8(11):5148-5157
pubmed: 31347292
Stem Cells. 2009 Feb;27(2):408-19
pubmed: 18988709
Biomed Pharmacother. 2021 Jun;138:111355
pubmed: 33706130
Clin Cancer Res. 2017 Sep 15;23(18):5489-5501
pubmed: 28559461
Nat Rev Cancer. 2004 Dec;4(12):978-87
pubmed: 15573119
Front Physiol. 2018 Mar 07;9:174
pubmed: 29563882